Subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, the company will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee and has decided on new executive candidates.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260210-05.pdf","jir_short_summary":"Subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, the company will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee and has decided on new executive candidates.","jir_summary":"### Overview of Executive Personnel Changes\nKobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee, subject to approval at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026. In line with this, at the Board of Directors meeting on February 10, 2026, the director candidates to be proposed to the Annual General Meeting of Shareholders were finalized. The candidates consist of eight directors not serving as Audit and Supervisory Committee members and three directors who will serve as Audit and Supervisory Committee members. Four auditors are scheduled to retire.\n\n### Skills Matrix of Director Candidates and Expectations for Enhancing Corporate Value\nThe director candidates possess diverse skills across corporate management, global business, organizational management, ESG and sustainability, finance and accounting, legal and risk management, and research & development. This aims to enhance corporate value and establish an effective supervisory function. Through optimizing the composition of executives, governance is expected to be strengthened as a company with an Audit and Supervisory Committee.","jir_financial_highlights":"Number of Director Candidates: 11 members (Unknown)\nNumber of Director Candidates Serving as Audit and Supervisory Committee Members: 3 members (Unknown)\nNumber of Auditors Scheduled to Retire: 4 members (Unknown)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #ExecutivePersonnelChanges, #CompanyWithAuditAndSupervisoryCommittee","jir_key_figures":"Number of Director Candidates Not Serving as Audit and Supervisory Committee Members: 8 members\nNumber of Director Candidates Serving as Audit and Supervisory Committee Members: 3 members\nNumber of Auditors Scheduled to Retire: 4 members","jir_meta_title":"Kobayashi Pharmaceutical Decides Executive Personnel Changes Accompanying Transition to Company with Audit and Supervisory Committee (March 2026)","jir_meta_description":"Kobayashi Pharmaceutical Co., Ltd. plans to transition to a company with an Audit and Supervisory Committee pending approval at the Annual General Meeting of Shareholders on March 27, 2026, and has decided on new director candidates to strengthen governance.","jir_og_title":"Kobayashi Pharmaceutical Announces Executive Personnel Changes Following Transition to Company with Audit and Supervisory Committee","jir_og_description":"At the Annual General Meeting in March 2026, approval is anticipated for the transition to a company with an Audit and Supervisory Committee and the new executive structure, aiming to enhance corporate value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-27081","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n